BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35790537)

  • 1. Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.
    Long Y; Lv X; Song X; Shao F; Ji H; Zhang Y; Qiao P; Liu Q; Xia X; Lei P; Gai Y; Lan X
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4156-4170. PubMed ID: 35790537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET Imaging of VLA-4 in a New BRAF
    Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
    Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
    Beaino W; Nedrow JR; Anderson CJ
    Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
    Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
    J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
    Beaino W; Anderson CJ
    J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evaluation of
    Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
    Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
    Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
    J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Al
    Gai Y; Yuan L; Sun L; Li H; Li M; Fang H; Altine B; Liu Q; Zhang Y; Zeng D; Lan X
    J Biol Inorg Chem; 2020 Feb; 25(1):99-108. PubMed ID: 31745667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
    Soodgupta D; Hurchla MA; Jiang M; Zheleznyak A; Weilbaecher KN; Anderson CJ; Tomasson MH; Shokeen M
    PLoS One; 2013; 8(2):e55841. PubMed ID: 23409060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma.
    Gai Y; Sun L; Lan X; Zeng D; Xiang G; Ma X
    Bioconjug Chem; 2018 Oct; 29(10):3483-3494. PubMed ID: 30205001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Metal-Free DOTA-Conjugated
    Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
    Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
    Haddad J; Latoche JD; Nigam S; Bellavia MC; Day KE; Zhu Q; Edwards WB; Anderson CJ; Tavakoli S
    J Nucl Med; 2021 Feb; 62(2):280-286. PubMed ID: 32680928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.
    Mattila JT; Beaino W; Maiello P; Coleman MT; White AG; Scanga CA; Flynn JL; Anderson CJ
    J Immunol; 2017 Jul; 199(2):806-815. PubMed ID: 28592427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo PET Tracking of
    Man F; Lim L; Volpe A; Gabizon A; Shmeeda H; Draper B; Parente-Pereira AC; Maher J; Blower PJ; Fruhwirth GO; T M de Rosales R
    Mol Ther; 2019 Jan; 27(1):219-229. PubMed ID: 30429045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
    Jiang M; Ferdani R; Shokeen M; Anderson CJ
    Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice.
    Perkins LA; Nyiranshuti L; Little-Ihrig L; Latoche JD; Day KE; Zhu Q; Tavakoli S; Sundd P; Novelli EM; Anderson CJ
    Blood Adv; 2020 Sep; 4(17):4102-4112. PubMed ID: 32882004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of PET Imaging for Prognostic Integrin α
    Huang CW; Hsieh WC; Hsu ST; Lin YW; Chung YH; Chang WC; Chiu H; Lin YH; Wu CP; Yen TC; Huang FT
    Theranostics; 2017; 7(16):4013-4028. PubMed ID: 29109795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Preclinical Evaluation of a
    Li H; Yuan L; Long Y; Fang H; Li M; Liu Q; Xia X; Qin C; Zhang Y; Lan X; Gai Y
    Mol Pharm; 2020 Aug; 17(8):3000-3008. PubMed ID: 32544337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of
    Maresca KP; Chen J; Mathur D; Giddabasappa A; Root A; Narula J; King L; Schaer D; Golas J; Kobylarz K; Rosfjord E; Keliher E; Chen L; Ram S; Pickering EH; Hardwick JS; Rejto PA; Hussein A; Ilovich O; Staton K; Wilson I; McCarthy TJ
    Mol Imaging Biol; 2021 Dec; 23(6):941-951. PubMed ID: 34143379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.